Media Contact

social-linkedin social-youtube  social-facebook  social-twitter  social-instagram

LabMind podcasts

View Factsheet PDF

Magnified image of molecules

July 21, 2022

Magnify Magazine, Summer 2022: Diagnostic Challenges of Autoimmune Neurologic Conditions, ARUP Awards, a Former Fellow’s Success

The Summer 2022 edition of Magnify, now online, features a look at the challenges of autoimmune neurologic testing, our experts in this area, and recent awards, and catches up with a former fellow.

A group of people stand in a lab

July 20, 2022

AACC 2022—Nearly 40 ARUP Experts to Lead Workshops, Scientific Sessions, and Poster Presentations

ARUP medical directors and scientists will share their research and expertise in areas like lab stewardship, biochemical genetics, and neonatal drug testing at AACC’s 2022 annual meeting in Chicago.

July 18, 2022

Q&A with ARUP’s Michael T. Pyne: Developing an NGS Assay for HIV-1 Antiretroviral Drug Resistance

Scientist Michael T. Pyne shares ARUP’s challenges and process of developing a next generation sequencing (NGS) test for HIV-1 antiretroviral drug resistance.

A male clinician discusses something with a male patient

ARUP Consult®, a free source of laboratory testing information for clinicians, released several new and updated resources in June.

July 6, 2022

ARUP Consult Offers New and Updated Resources on Immunobullous Diseases, Diabetes, and Prostate Cancer

ARUP Consult, a free source of expert guidance in laboratory testing, has released new and updated resources on testing for immunobullous diseases, diabetes mellitus, and prostate cancer.

Illustration of cells

June 23, 2022

ARUP Launches New Interactive Tool to Compare and Choose Immunobullous Disease Tests

ARUP offers several antibody panels to test for immunobullous diseases, which are difficult to diagnose. The Immunobullous Disease Testing Comparison tool allows users to quickly compare test options.

A lab tech pipettes a sample

June 15, 2022

ARUP Leadership: VALID Act’s Proposed Regulations Would Raise Costs, Hinder Research, and Limit Patient Care

ARUP experts say that the VALID Act, which would require FDA approval of all lab-developed tests, would add administrative and financial burdens to an already safe and effective validation process.

Media Contact

social-linkedin social-youtube  social-facebook  social-twitter  social-instagram

LabMind podcasts

View Factsheet PDF